vs
ALT5 Sigma Corp（ALTS）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是ALT5 Sigma Corp的1.7倍（$9.1M vs $5.4M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -7100.2%，领先7039.8%），ALT5 Sigma Corp同比增速更快（12.5% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-7.2M）
ALT5 Sigma Corp是一家专注于数字资产基础设施及交易解决方案的金融科技企业，面向全球零售和机构客户提供受监管的数字资产现货及衍生品交易、安全托管及高效结算服务，核心市场覆盖北美、欧洲及亚太多个国家和地区。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
ALTS vs PLX — 直观对比
营收规模更大
PLX
是对方的1.7倍
$5.4M
营收增速更快
ALTS
高出62.4%
-49.9%
净利率更高
PLX
高出7039.8%
-7100.2%
自由现金流更多
PLX
多$8.8M
$-7.2M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.4M | $9.1M |
| 净利润 | $-381.5M | $-5.5M |
| 毛利率 | 40.9% | 49.4% |
| 营业利润率 | -38.1% | -51.1% |
| 净利率 | -7100.2% | -60.3% |
| 营收同比 | 12.5% | -49.9% |
| 净利润同比 | -7249.1% | -184.8% |
| 每股收益（稀释后） | $-5.53 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALTSPLX
| Q4 25 | $5.4M | $9.1M | ||
| Q3 25 | $7.6M | $17.9M | ||
| Q2 25 | $6.4M | $15.7M | ||
| Q1 25 | $5.5M | $10.1M | ||
| Q4 24 | $4.8M | $18.2M | ||
| Q3 24 | $4.9M | $18.0M | ||
| Q2 24 | $2.2M | $13.5M | ||
| Q1 24 | $0 | — |
净利润ALTSPLX
| Q4 25 | $-381.5M | $-5.5M | ||
| Q3 25 | $49.0M | $2.4M | ||
| Q2 25 | $-9.1M | $164.0K | ||
| Q1 25 | $-2.9M | $-3.6M | ||
| Q4 24 | $-5.2M | $6.5M | ||
| Q3 24 | $-822.0K | $3.2M | ||
| Q2 24 | $589.0K | $-2.2M | ||
| Q1 24 | $-2.1M | — |
毛利率ALTSPLX
| Q4 25 | 40.9% | 49.4% | ||
| Q3 25 | 34.6% | 53.4% | ||
| Q2 25 | 43.5% | 62.5% | ||
| Q1 25 | 47.0% | 19.1% | ||
| Q4 24 | 45.8% | 78.7% | ||
| Q3 24 | 47.8% | 53.4% | ||
| Q2 24 | 50.6% | 29.8% | ||
| Q1 24 | — | — |
营业利润率ALTSPLX
| Q4 25 | -38.1% | -51.1% | ||
| Q3 25 | -218.3% | 11.9% | ||
| Q2 25 | -32.8% | 7.5% | ||
| Q1 25 | -39.4% | -41.0% | ||
| Q4 24 | -40.8% | 39.6% | ||
| Q3 24 | -14.8% | 22.2% | ||
| Q2 24 | -112.2% | -18.0% | ||
| Q1 24 | — | — |
净利率ALTSPLX
| Q4 25 | -7100.2% | -60.3% | ||
| Q3 25 | 646.4% | 13.2% | ||
| Q2 25 | -142.9% | 1.0% | ||
| Q1 25 | -51.9% | -35.8% | ||
| Q4 24 | -108.7% | 35.6% | ||
| Q3 24 | -16.6% | 18.0% | ||
| Q2 24 | 27.2% | -16.4% | ||
| Q1 24 | — | — |
每股收益（稀释后）ALTSPLX
| Q4 25 | $-5.53 | $-0.06 | ||
| Q3 25 | $0.29 | $0.03 | ||
| Q2 25 | $-0.49 | $0.00 | ||
| Q1 25 | $-0.18 | $-0.05 | ||
| Q4 24 | $-0.35 | $0.10 | ||
| Q3 24 | $-0.06 | $0.03 | ||
| Q2 24 | $0.07 | $-0.03 | ||
| Q1 24 | $-0.34 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.2M | $14.7M |
| 总债务越低越好 | $563.0K | — |
| 股东权益账面价值 | $1.2B | $48.2M |
| 总资产 | $1.2B | $82.3M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ALTSPLX
| Q4 25 | $6.2M | $14.7M | ||
| Q3 25 | $7.3M | $13.6M | ||
| Q2 25 | $9.6M | $17.9M | ||
| Q1 25 | $10.8M | $19.5M | ||
| Q4 24 | $7.2M | $19.8M | ||
| Q3 24 | $8.7M | $27.4M | ||
| Q2 24 | $5.8M | $23.4M | ||
| Q1 24 | $61.0K | — |
总债务ALTSPLX
| Q4 25 | $563.0K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $563.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALTSPLX
| Q4 25 | $1.2B | $48.2M | ||
| Q3 25 | $1.6B | $52.9M | ||
| Q2 25 | $26.1M | $49.9M | ||
| Q1 25 | $21.8M | $45.2M | ||
| Q4 24 | $12.4M | $43.2M | ||
| Q3 24 | $20.2M | $32.4M | ||
| Q2 24 | $22.9M | $28.6M | ||
| Q1 24 | $3.8M | — |
总资产ALTSPLX
| Q4 25 | $1.2B | $82.3M | ||
| Q3 25 | $1.6B | $82.3M | ||
| Q2 25 | $94.7M | $78.5M | ||
| Q1 25 | $78.0M | $73.9M | ||
| Q4 24 | $75.7M | $73.4M | ||
| Q3 24 | $74.9M | $61.6M | ||
| Q2 24 | $75.4M | $91.5M | ||
| Q1 24 | $18.6M | — |
负债/权益比ALTSPLX
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-7.2M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-7.2M | $1.6M |
| 自由现金流率自由现金流/营收 | -133.4% | 17.8% |
| 资本支出强度资本支出/营收 | 0.2% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流ALTSPLX
| Q4 25 | $-7.2M | $2.0M | ||
| Q3 25 | $-8.7M | $-3.7M | ||
| Q2 25 | $-5.2M | $-5.2M | ||
| Q1 25 | $-1.5M | $-5.1M | ||
| Q4 24 | $1.8M | $4.0M | ||
| Q3 24 | $4.2M | $4.1M | ||
| Q2 24 | $80.0K | $-3.6M | ||
| Q1 24 | $-544.0K | — |
自由现金流ALTSPLX
| Q4 25 | $-7.2M | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率ALTSPLX
| Q4 25 | -133.4% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度ALTSPLX
| Q4 25 | 0.2% | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
现金转化率ALTSPLX
| Q4 25 | — | — | ||
| Q3 25 | -0.18× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALTS
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
